520 related articles for article (PubMed ID: 23642545)
21. Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
Soerensen AV; Donskov F; Kjellberg J; Ibsen R; Hermann GG; Jensen NV; Fode K; Geertsen PF
Eur Urol; 2015 Sep; 68(3):516-22. PubMed ID: 25533417
[TBL] [Abstract][Full Text] [Related]
22. Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw.
Haidar A; Jønler M; Folkmar TB; Lund L
Scand J Urol Nephrol; 2009; 43(6):442-4. PubMed ID: 19903091
[TBL] [Abstract][Full Text] [Related]
23. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
Beuselinck B; Wolter P; Karadimou A; Elaidi R; Dumez H; Rogiers A; Van Cann T; Willems L; Body JJ; Berkers J; Van Poppel H; Lerut E; Debruyne P; Paridaens R; Schöffski P
Br J Cancer; 2012 Nov; 107(10):1665-71. PubMed ID: 23132391
[TBL] [Abstract][Full Text] [Related]
24. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
Iacovelli R; Palazzo A; Trenta P; Mezi S; Pellegrino D; Naso G; Cortesi E
Am J Clin Oncol; 2014 Dec; 37(6):611-5. PubMed ID: 23388560
[TBL] [Abstract][Full Text] [Related]
25. Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study.
Guillot A; Joly C; Barthélémy P; Meriaux E; Negrier S; Pouessel D; Chevreau C; Mahammedi H; Houede N; Roubaud G; Gravis G; Tartas S; Albiges L; Vassal C; Oriol M; Tinquaut F; Espenel S; Bouleftour W; Culine S; Fizazi K
Clin Genitourin Cancer; 2019 Feb; 17(1):e38-e43. PubMed ID: 30279115
[TBL] [Abstract][Full Text] [Related]
26. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
[TBL] [Abstract][Full Text] [Related]
27. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract][Full Text] [Related]
28. Targeted therapies in metastatic renal cancer in 2009.
Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A
BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
[TBL] [Abstract][Full Text] [Related]
29. Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy.
Mignogna MD; Fedele S; Lo Russo L; Ciccarelli R; Lo Muzio L
J Clin Oncol; 2006 Mar; 24(9):1475-7. PubMed ID: 16549843
[No Abstract] [Full Text] [Related]
30. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
Beuselinck B; Lerut E; Wolter P; Dumez H; Berkers J; Van Poppel H; Joniau S; Oyen R; De Wever L; Strijbos M; Paridaens R; Schöffski P
Clin Genitourin Cancer; 2014 Oct; 12(5):e205-14. PubMed ID: 24861951
[TBL] [Abstract][Full Text] [Related]
31. An update on targeted therapy in metastatic renal cell carcinoma.
Lombardi G; Zustovich F; Donach M; Dalla Palma M; Nicoletto O; Pastorelli D
Urol Oncol; 2012; 30(3):240-6. PubMed ID: 20456985
[TBL] [Abstract][Full Text] [Related]
32. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
Scagliotti GV; Hirsh V; Siena S; Henry DH; Woll PJ; Manegold C; Solal-Celigny P; Rodriguez G; Krzakowski M; Mehta ND; Lipton L; García-Sáenz JA; Pereira JR; Prabhash K; Ciuleanu TE; Kanarev V; Wang H; Balakumaran A; Jacobs I
J Thorac Oncol; 2012 Dec; 7(12):1823-1829. PubMed ID: 23154554
[TBL] [Abstract][Full Text] [Related]
33. Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC).
Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup
Ann Acad Med Singap; 2015 Oct; 44(10):406-14. PubMed ID: 26763058
[TBL] [Abstract][Full Text] [Related]
34. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
Blesius A; Beuselinck B; Chevreau C; Ravaud A; Rolland F; Oudard S; Escudier B
Clin Genitourin Cancer; 2013 Jun; 11(2):128-33. PubMed ID: 23332872
[TBL] [Abstract][Full Text] [Related]
35. Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature.
Fusco V; Porta C; Saia G; Paglino C; Bettini G; Scoletta M; Bonacina R; Vescovi P; Merigo E; Lo Re G; Guglielmini P; Di Fede O; Campisi G; Bedogni A
Clin Genitourin Cancer; 2015 Aug; 13(4):287-294. PubMed ID: 25586958
[TBL] [Abstract][Full Text] [Related]
36. Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma.
Orita Y; Sugitani I; Toda K; Manabe J; Fujimoto Y
Thyroid; 2011 Jan; 21(1):31-5. PubMed ID: 21058881
[TBL] [Abstract][Full Text] [Related]
37. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
[TBL] [Abstract][Full Text] [Related]
38. [Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?].
Ivanyi P; Grünwald V
Aktuelle Urol; 2015 Nov; 46(6):467-72. PubMed ID: 26556569
[TBL] [Abstract][Full Text] [Related]
39. Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Buchler T; Bortlicek Z; Poprach A; Pavlik T; Veskrnova V; Honzirkova M; Zemanova M; Fiala O; Kubackova K; Slaby O; Svoboda M; Vyzula R; Dusek L; Melichar B;
Eur Urol; 2016 Sep; 70(3):469-75. PubMed ID: 26746623
[TBL] [Abstract][Full Text] [Related]
40. [Medical treatment of renal cell carcinoma].
Guy L; Bay JO; Bastide C; Mahammedi H; Bruyere F; Karsenty G
Prog Urol; 2013 Nov; 23(15):1225-37. PubMed ID: 24183081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
